Boosting ROS‐Mediated Lysosomal Membrane Permeabilization for Cancer Ferroptosis Therapy
Advanced Healthcare Materials · 2023-03 · 12 (6)
DOI: 10.1002/adhm.202202150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 04.12.2022. Verfasst von Ying Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmaceutical Sciences, Guizhou Medical University, Universit…. Hauptthemen laut MEDLINE: Ferroptosis, Neoplasms. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Due to the deficient catalase, abundant reduced iron and low acidic environment in lysosomes, inducing lysosomal membrane permeabilization (LMP) through Fenton reaction‐based reactive oxygen species (ROS) generation recently attracts increasing attention in cancer therapy. However, the lysosomal membranes are protected by highly glycosylated membrane proteins and several endolysosomal damage‐response mechanisms can rapidly repair the injured lysosomes. To produce sufficient ROS and cause complete lysosomal membranes rupture, a lysosome‐targeted ROS inducer, N ‐(3‐Aminopropyl) morpholine grafted cross‐linked lipoic acid vesicles with vitamin C‐loading (VC@ N3AM cLAVs), is developed. VC@ N3AM cLAVs efficiently accumulate in lysosomes and convert into two redox couples LA/DHLA (dihydrolipoic acid, reduced form of LA) and VC/DHA (dehydroascorbic acid, oxidized form of VC) by the lysosomal glutathione, which can not only produce a large amount of H 2 O 2 by pro‐oxidant action but also accelerate iron transformation through the cyclic redox reactions between each other and cause the efficient conversion of the generated H 2 O 2 into highly toxic •OH. Both in vitro and in vivo experiments demonstrate that VC@ N3AM cLAVs can effectively enhance ROS production and boost LMP, finally initiation irreversible death of tumor cells via ferroptosis pathway, thus representing a potential anticancer drug for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The State Key Laboratory of Functions and Applications of Medicinal Plants & School of Pharmaceutical Sciences, Guizhou Medical University, University Town, Guian New District, Guiyang, 550025, China.
- The Department of Pharmacology of Materia Medical (the High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province, the Key Laboratory of Optimal Utilization of Natural Medicine Resou…
ORCID-Profile: Ying Chen
Zitieren
APA
Chen, Y., Yang, Z., Wang, S., Ma, Q., Li, L., Wu, X., Guo, Q., Tao, L., & Shen, X. (2023). Boosting ROS‐Mediated Lysosomal Membrane Permeabilization for Cancer Ferroptosis Therapy. Advanced Healthcare Materials, 12(6). https://doi.org/10.1002/adhm.202202150
Vancouver
Chen Y, Yang Z, Wang S, Ma Q, Li L, Wu X, et al. Boosting ROS‐Mediated Lysosomal Membrane Permeabilization for Cancer Ferroptosis Therapy. Advanced Healthcare Materials. 2023;12(6). doi:10.1002/adhm.202202150
BibTeX
@article{Chen2023,
author = {Chen, Ying and Yang, Zengqiu and Wang, Sibu and Ma, Qin and Li, Lingyan and Wu, Xingjie and Guo, Qianqian and Tao, Ling and Shen, Xiangchun},
title = {Boosting ROS‐Mediated Lysosomal Membrane Permeabilization for Cancer Ferroptosis Therapy},
journal = {Advanced Healthcare Materials},
year = {2023},
volume = {12},
number = {6},
doi = {10.1002/adhm.202202150}
}
EUVIMED